pemafibrate
Kowa Pharmaceuticals
[]
no significant difference in the incidence of composite cvd outcomes between pemafibrate and placebo in pts with dm, htg and low hdl.
warning renal adverse outcome &amp; venous thrombosis. #aha22 #latebreaking #prominent #nejm 
Postdoc in epi dept. @JohnsHopkinsSPH @JohnsHopkinsEPI @JHUWelchCenter. MD. (Cardiologist) PhD. (cardiovascular medicine) Fellow of the ESC (FESC).